In the present case, according to the guidelines for the management of CUP [3], osteoblastic bone metastases in a patient with a markedly elevated PSA level suggests metastatic PSA+ cancer, and hormone-based treatment is recommended if the primary lesion is not detected within 1 month. The gene discussed is KLK3; the disease is cancer.